About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. María Ángeles Moro. Leader of the Neurovascular Pathophysiology Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC). She is also Coordinator of the CNIC “Cardiovascular Risk Factors and Brain Health” programme, co-leads the Neurovascular Research Unit (UCM) and participates in the Neurovascular Diseases Group of the i+12 Health Research Institute (Health Research Institute of Hospital 12 de Octubre).
Summary: Ischemic stroke remains a leading cause of death and long-term disability worldwide. Despite major advances in reperfusion therapies, clinical outcome is still highly variable, and many patients experience incomplete tissue reperfusion and poor recovery. Understanding the biological mechanisms that regulate microvascular flow and tissue injury after stroke is therefore essential for improving patient outcomes. In recent years, immunothrombosis has emerged as a key contributor to cerebrovascular injury. Neutrophils, through the formation of neutrophil extracellular traps (NETs), can promote microvascular obstruction, amplify inflammation, and impair tissue perfusion. While NETs have been implicated in stroke severity and resistance to reperfusion, the factors that govern when and how these processes are activated remain largely unknown. In this seminar, I will present evidence that circadian rhythms critically shape neutrophil function and NET formation after ischemic stroke, thereby influencing collateral circulation, microvascular perfusion, and infarct size. Using complementary experimental models and clinical data from stroke patients, we identify time-of-day–dependent neutrophil states that determine the extent of immunothrombosis and tissue injury. Finally, we will discuss the translational implications of these findings, and future avenues to improve therapy and outcomes in cerebrovascular disease.
Host: Dr. Anna Rosell. Head of group Neurovascular Diseases. Vall d'Hebron Research Institute (VHIR)
Online: https://gencat.zoom.us/j/84956123045